Document Detail


The regulation of growth in glycogen storage disease type 1.
MedLine Citation:
PMID:  12608939     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To study endocrine and metabolic variables that affect growth in patients with glycogen storage disease type 1 (GSD-1) receiving standard dietary therapy. DESIGN: Observational study. PATIENTS AND MEASUREMENTS: Thirty-eight patients with GSD-1, age range 0.6-32.9 years, were investigated on their usual dietary regimens. Data on height, height velocity in prepubertal children, endocrine and metabolic responses to oral glucose load, 24-h serum cortisol and GH concentration profiles and serum IGF-1 concentrations were collected. RESULTS: The population studied was shorter than average, with a median height standard deviation score (SDS) of -1.60, but significantly taller than a historical population studied at the same institution that had not received dietary therapy at the time of study. A wide range of height SDS was encountered (-5.28 to 1.21) and a subset still exhibit marked growth failure. Median body mass index (BMI) SDS was 0.72 (range -1.34 to 3.96). Those patients with the greatest BMI SDS had the lowest serum GH concentrations but serum IGF-1 concentrations were within the normal range. Patients with the poorest growth exhibit low serum insulin concentration responses to glucose load, GH insensitivity and higher mean 24-h plasma cortisol levels when compared to those patients who were better grown. CONCLUSION: This study shows that overall the growth of this group of patients with glycogen storage disease type 1 has improved compared to that of a historical control group. There remains a subset of this population with poor growth despite therapy. The measured endocrine responses in this subset are similar to those reported for untreated patients. To improve the growth further in these individuals it will be necessary to understand whether this is failure of prescribed therapy or failure to comply with therapy.
Authors:
Helen R Mundy; Peter C Hindmarsh; David R Matthews; James V Leonard; Philip J Lee
Related Documents :
20857059 - Biochemical acromegaly in patients with prolactinoma during treatment with dopaminergic...
2832289 - Crh in cushing's syndrome.
15937939 - Cause of sudden, unexpected death of prader-willi syndrome patients with or without gro...
24110849 - Comparison of complexity of emg signals between a normal subject and a patient after st...
1759539 - Chronic treatment with parlodel lar of patients with prolactin-secreting tumours. diffe...
2357279 - Pituitary enlargement and hyperprolactinaemia due to primary hypothyroidism: errors and...
13561109 - Cardiac operations under direct vision; experience with extracoporeal oxygenation of th...
19967149 - Fibrin clot properties are altered in patients with chronic obstructive pulmonary disea...
18447659 - Amino acid requirements in critically ill patients with acute kidney injury treated wit...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  58     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-02-28     Completed Date:  2003-05-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  England    
Other Details:
Languages:  eng     Pagination:  332-9     Citation Subset:  IM    
Affiliation:
The London Centre for Paediatric Endocrinology and Metabolism, Institute of Child Health, London, UK. helen.mundy@uclh.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Body Height
Body Mass Index
Child
Child, Preschool
Glucose Tolerance Test
Glycogen Storage Disease Type I / blood,  complications*,  diet therapy,  physiopathology
Growth Disorders / blood,  etiology*
Growth Hormone / blood
Humans
Hydrocortisone / blood
Infant
Insulin / blood
Insulin-Like Growth Factor I / analysis
Treatment Outcome
Chemical
Reg. No./Substance:
11061-68-0/Insulin; 50-23-7/Hydrocortisone; 67763-96-6/Insulin-Like Growth Factor I; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carriers for type II 3beta-hydroxysteroid dehydrogenase (HSD3B2) deficiency can only be identified b...
Next Document:  Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWA...